Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interim analyses for randomized clinical trials: the group sequential approach

S J Pocock

    Biometrics
    |March 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics.

    British journal of clinical pharmacology·2012
    Same author

    [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies].

    Der Internist·2008
    Same author

    Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis.

    Evidence-based medicine·2007
    Same author

    The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.

    Heart (British Cardiac Society)·2007
    Same author

    Rosiglitazone RECORD study: glucose control outcomes at 18 months.

    Diabetic medicine : a journal of the British Diabetic Association·2007
    Same author

    Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.

    Heart (British Cardiac Society)·2006
    Same journal

    Fast penalized generalized estimating equations for large longitudinal functional datasets.

    Biometrics·2026
    Same journal

    Causally-interpretable random-effects meta-analysis.

    Biometrics·2026
    Same journal

    Statistical inference for mean function of partially observed functional time series.

    Biometrics·2026
    Same journal

    Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

    Biometrics·2026
    Same journal

    Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

    Biometrics·2026
    Same journal

    Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

    Biometrics·2026
    See all related articles

    Group sequential designs allow early trial stopping for significant treatment differences. Analyzing data more than five times offers minimal benefit unless expecting very large effects.

    Area of Science:

    • Clinical Trial Design
    • Biostatistics
    • Medical Research Methodology

    Background:

    • Clinical trials often include periodic interim analyses to assess efficacy and safety.
    • A key purpose of interim analyses is to determine if a trial should be stopped early due to substantial treatment differences.

    Purpose of the Study:

    • To evaluate the utility and statistical advantages of group sequential designs in clinical trials.
    • To determine optimal strategies for interim analyses, including the number of analyses and significance level adjustments.

    Main Methods:

    • Group sequential designs were employed, involving repeated significance tests on accumulating data.
    • Power calculations, utilizing numerical integration for normal group sequential designs, were performed.
    • The study considered varying nominal significance levels across different stages of the trial.

    Related Experiment Videos

    Main Results:

    • There is limited statistical advantage in conducting more than five interim analyses, unless anticipating extremely large treatment differences.
    • Adjusting significance levels to be more stringent early on and less stringent later does not offer statistical advantages for adequately powered trials.

    Conclusions:

    • Group sequential designs provide a framework for early trial termination based on accumulating data.
    • The number of interim analyses should be carefully considered, with diminishing returns beyond five occasions.
    • Altering significance levels across trial stages does not enhance statistical power or efficiency in adequately sized trials.